SIREN : 830463535
PHARMA FB is a French company founded 8 years ago, specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé. Based in ANNAY (62880), this company of category PME shows in 2019 a revenue of 1.6 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-02
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|
| Revenue | N/C | N/C | N/C | N/C | N/C | 1 576 879 € | 1 697 498 € |
| Net income | 52 793 € | 64 921 € | 105 490 € | -99 381 € | 93 235 € | 76 497 € | 22 566 € |
| EBITDA | N/C | N/C | N/C | N/C | N/C | 182 101 € | 72 232 € |
| Net margin | N/C | N/C | N/C | N/C | N/C | 4.9% | 1.3% |
In 2024, PHARMA FB generates positive net income of 53 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2018-2024: 23 k€ -> 53 k€.
52 793 €
The debt ratio (= Financial debt / Equity x 100) stands at 191%. Critical situation: debt significantly exceeds equity, severely limiting borrowing capacity and exposing the company to default risk. Financial autonomy (= Equity / Total assets x 100) reaches 29%. The balance between equity and debt is satisfactory.
190.54%
29.343%
35.6%
In 2024, the debt ratio of PHARMA FB (190.54) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
In 2024, the financial autonomy of PHARMA FB (29.3%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
The liquidity ratio (= Current assets / Current liabilities) stands at 114.08. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
114.084
In 2024, the liquidity ratio of PHARMA FB (114.08) ranks in the bottom 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio below 1 may signal potential cash flow tensions.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.
0 €
0 j
0 j
0 j
Based on 225 transactions of similar company sales in 2024, the value of PHARMA FB is estimated at 737 029 € (range 513 255€ - 1 102 638€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Only this financial indicator is available for this company.
This estimate is based on the analysis of 225 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare PHARMA FB with other companies in the same sector:
The revenue of PHARMA FB in 2019 is 1.6 M€.
Yes, PHARMA FB generated a net profit of 53 k€ in 2024.
The headquarters of PHARMA FB is located in ANNAY (62880), in the department Pas-de-Calais.
The tax return of PHARMA FB is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
PHARMA FB operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.